FJMUNi001-A
General
Cell Line |
|
| hPSCreg name | FJMUNi001-A |
| Cite as: | FJMUNi001-A (RRID:CVCL_C0FR) |
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
CENSOi003-B (FB79R2c6, CENSOi258) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi005-A (FB76R2c5, CENSOi245) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi007-A (FB75R2c5, CENSOi255) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi001-B (FB78R2c2, CENSOi249) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi002-B (FB74R2c4, CENSOi261) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy HIHDNDi001-A (A30P-3, SNCA3, Tue_020_A) Donor's gene variants: SNCA, SNCA, SNCA Donor diseases: autosomal dominant Parkinson disease 1 RNRMUi005-A (EB-iPSC-d4, RDEB-iPSC-d4) Donor diseases: Epidermolysis Bullosa Simplex recessive dystrophic epidermolysis bullosa HIHDNDi001-B (A30P-4, SNCA4, Tue_020_B) Donor's gene variants: SNCA, SNCA, SNCA Donor diseases: autosomal dominant Parkinson disease 1 HDZi003-A (hiPSC NP0038) Donor's gene variants: TMEM43 Donor diseases: arrhythmogenic right ventricular dysplasia 5 |
| Last update | 25th February 2022 |
| User feedback | |
Provider |
|
| Generator | Department of Neurology, Fujian Institute of Neurology, the First Affiliated Hospital, Fujian Medical University (FJMUN) |
| Owner | Department of Neurology, Fujian Institute of Neurology, the First Affiliated Hospital, Fujian Medical University (FJMUN) |
| Distributors | |
| Derivation country | China |
External Databases |
|
| BioSamples | SAMEA12095262 |
| Cellosaurus | CVCL_C0FR |
| Wikidata | Q112929563 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA12095263 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | the First Affiliated Hospital, Fujian Medical University |
| Approval number | 闽医大附一伦理医研【2018】019号 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type |
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR, Sequencing
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
Accutase
|
| CO2 Concentration | 5 % |
| Medium |
Other medium:
Base medium: ncTarget hiPSC Medium
Main protein source: Serum concentration: % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| NANOG |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
karyogram
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.